DAVID GALLARDO GIRALT

Hematologia

Castellet H, Ramil G, Carricondo M, Oñate G, Garrido A, Artigas A, Pratcorona M, Salamero O, Cortés-Bullich A, Vives S, Tormo M, Mascaró M, Gallardo D, Tutusaus JMM, Garcia A, Sierra J, Esteve J, Nomdedéu J

Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.

EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114, 1052-1054 dx.doi.org/10.1111/ejh.14402

Hematologia

Nihtilä J, Salmenniemi U, Itälä-Remes M, Crossland RE, Gallardo D, Bogunia-Kubik K, Lacina P, Bieniaszewska M, Giebel S, Hyvärinen K, Kekäläinen E, Ritari J, Partanen J

Donor genetic determinant of thymopoiesis, rs2204985, and stem cell transplantation outcome in a multipopulation cohort

HUMAN IMMUNOLOGY, 2024, 85, 110791-110791 dx.doi.org/10.1016/j.humimm.2024.110791

Hematologia

Gonzalez-Montes, Y, Osca-Gelis, G, Rodriguez-Romanos, R, Villavicencio, A, González-Bártulos, M, Llopis, F, Clapes, V, Oriol, A, Sureda, A, Escoda, L, Sarrà, J, Garzó, A, Lloveras, N, Gómez, B, Granada, I, Gallardo, D

CD200 genotype is associated with clinical outcome of patients with multiple myeloma

Frontiers in Immunology, 2024, 15, 1252445-1252445 dx.doi.org/10.3389/fimmu.2024.1252445

Hematologia

Nihtilä J, Penna L, Salmenniemi U, Itälä-Remes M, Crossland RE, Gallardo D, Bogunia-Kubik K, Lacina P, Bieniaszewska M, Giebel S, Karjalainen K, Jahan F, Kerkelä E, Hyvärinen K, Koskela S, Ritari J, Partanen J

Effect of NK cell receptor genetic variation on allogeneic stem cell transplantation outcome and in vitro NK cell cytotoxicity.

SCIENTIFIC REPORTS, 2024, 14, 26988-26988 dx.doi.org/10.1038/s41598-024-78619-5

Hematologia

Sanchez, JLP, Ljungman, P, Kulagin, A, Stanghellini, MTL, Solano, C, Tridello, G, Mayer, J, Suarez-Lled , M, Labussi re-Wallet, H, Zeiser, R, Clay, J, Sandstedt, AB, Heras, I, Kalwak, K, Lopez, JL, Schaffrath, J, Balduzzi, A, Benedetti, F, Hayat, A, Gallardo, D, Koene, H, Rif n, J, Schlegel, PG, Knelange, N, Averbuch, D, De la Camara, R

SARS-COV-2 CYCLE THRESHOLD LEVELS AND COVID-19 OUTCOME IN ALLOGENEIC STEM CELL TRANSPLANTATION. AN INFECTIOUS DISEASE WORKING PARTY STUDY

BONE MARROW TRANSPLANTATION, 2024, 59, 441-442

Hematologia

Tammi, S, Nihtila, J, Koskela, S, Hyvarinen, K, Salmenniemi, U, Itala-Remes, M, Crossland, RE, Gallardo, D, Bogunia-Kubik, K, Lacina, P, Bieniaszewska, M, Giebel, S, Partanen, J, Ritari, J

IMPACT OF MIC AND NON-CLASSICAL HLA-E, -F AND -G ALLELES AND THEIR MISMATCHING TOGETHER WITH CLINICAL DATA ON ALLO-HSCT COMPLICATIONS

BONE MARROW TRANSPLANTATION, 2024, 59, 771-771

Hematologia

Nihtil , J, Salmenniemi, U, It l -Remes, M, Crossland, RE, Gallardo, D, Bogunia-Kubik, K, Lacina, P, Bieniaszewska, M, Giebel, S, Koskela, S, Hyv rinen, K, Partanen, J, Ritari, J

WHOLE GENOME MATCHING ANALYSIS FOR GRAFT-VERSUS-HOST DISEASE AND RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

BONE MARROW TRANSPLANTATION, 2024, 59, 768-768

Hematologia

Oliveira AC, Roncero JM, Ferrá C, Do Nascimento J, Rodriguez-Luaces M, Encuentra M, Domingo-Domenech E, López P, Gallardo D, Ribera JM, Sarrá J, Sureda A, González-Barca E

Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117, 388-397 dx.doi.org/10.1007/s12185-022-03488-5

Hematologia

Cruz D, Rodríguez-Romanos R, González-Bartulos M, García-Cadenas I, de la Cámara R, Heras I, Buño I, Santos N, Lloveras N, Velarde P, Tuset E, Martínez C, González M, Sanz GF, Ferrá C, Sampol A, Coll R, Pérez-Simón JA, López-Jiménez J, Jurado M, Gallardo D

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors

Frontiers in Immunology, 2023, 14, 1066393-1066393 dx.doi.org/10.3389/fimmu.2023.1066393

Hematologia

Gonzalez-Montes Y, Rodriguez-Romanos R, Villavicencio A, Osca-Gelis G, González-Bártulos M, Llopis F, Clapes V, Oriol A, Sureda A, Escoda L, Sarrà J, Garzó A, Lloveras N, Díez I, Granada I, Gallardo D

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma

Frontiers in Immunology, 2023, 14, 1158105-1158105 dx.doi.org/10.3389/fimmu.2023.1158105

Directori

Publicacions

Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.

Donor genetic determinant of thymopoiesis, rs2204985, and stem cell transplantation outcome in a multipopulation cohort

CD200 genotype is associated with clinical outcome of patients with multiple myeloma

Effect of NK cell receptor genetic variation on allogeneic stem cell transplantation outcome and in vitro NK cell cytotoxicity.

SARS-COV-2 CYCLE THRESHOLD LEVELS AND COVID-19 OUTCOME IN ALLOGENEIC STEM CELL TRANSPLANTATION. AN INFECTIOUS DISEASE WORKING PARTY STUDY

IMPACT OF MIC AND NON-CLASSICAL HLA-E, -F AND -G ALLELES AND THEIR MISMATCHING TOGETHER WITH CLINICAL DATA ON ALLO-HSCT COMPLICATIONS

WHOLE GENOME MATCHING ANALYSIS FOR GRAFT-VERSUS-HOST DISEASE AND RELAPSE AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma

Formulari de contacte

Coneix l’IDIBGI!